Still Disease — Research Summary
Printed from RareWays (rareways.com.au) on 12 September 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Identification of potential diagnostic biomarkers for systemic juvenile idiopathic arthritis by integrative transcriptomic analysis.
Wang Jingwei et al. — Autoimmunity (31 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41579068/
- 2.
Membranous-like glomerulopathy with masked IgG-k deposits in a pediatric patient with juvenile idiopathic arthritis.
Chati Priyanka et al. — Pediatric nephrology (Berlin, Germany) (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/40954329/
- 3.
Long-term remission and monocyclic course in Still's disease patients starting canakinumab early: data from the international AIDA network registry.
Vitale Antonio et al. — Seminars in arthritis and rheumatism (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42364377/
- 4.
Research definitions of flare in non-systemic juvenile idiopathic arthritis: An OMERACT scoping review.
Kitson Mariya Farah et al. — Seminars in arthritis and rheumatism (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42612507/
- 5.
Macrophage activation syndrome in systemic lupus erythematosus and Still's disease: distinct phenotypes shaped by the underlying diseases.
Tonutti Antonio et al. — Rheumatology (Oxford, England) (11 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42726099/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
Recruiting — Phase 3 — AbbVie
https://clinicaltrials.gov/study/NCT05609630
- 2.
AutoInflammatory Disease Alliance Registry (AIDA)
Recruiting — University of Siena
https://clinicaltrials.gov/study/NCT05200715
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Still Disease
Still disease is a rare inflammatory condition that causes spiking fevers, a salmon-coloured rash, and joint pain and swelling. It can begin in childhood, where it is called systemic-onset juvenile idiopathic arthritis, or in adulthood. Treatment uses steroids and medicines that block interleukin-1 or interleukin-6 to settle inflammation and protect the joints.
Most Recent Research
The current diagnostic criteria for systemic juvenile idiopathic arthritis (sJIA) lack specificity. Diagnostic biomarkers are in urgent need to help with the early diagnosis of sJIA. Gene expression data of a JIA cohort study from Gene Expression Omnibus (GEO) database was adopted to get hub genes of sJIA by using integrated bioinformatic analysis including differentially expressed gene (DEG) analysis, weighted coexpression network analysis (WGCNA) and protein‒protein network interaction (PPI) analysis. Least absolute shrinkage and selection operator (LASSO) regression analysis was subsequently applied to identify biomarkers with the highest diagnostic potential for sJIA among these hub genes. A prediction model based on the identified biomarkers was constructed and subsequently validated in three additional independent GEO cohorts. Totally 761 DEGs were obtained by comparing gene expression profiles between sJIA patients and healthy controls. Twenty-two hub genes were identified by integrating WGCNA and PPI network analysis. All hub genes underwent LASSO regression analysis and three genes-ALAS2, S100A9, and S100A12-were eventually identified as the most promising diagnostic biomarkers. A prediction nomogram model based on these three genes was constructed, yielding an area under the curve (AUC) of 0.9337, and was subsequently validated in independent validation datasets, achieving AUC values of 0.9412, 0.9018, and 0.7064. The genes ALAS2, S100A9, and S100A12 showed significant association to sJIA and may serve as candidate diagnostic biomarkers pending further clinical validation.
Common Questions
What is Still Disease?
Still disease is a rare inflammatory condition that causes spiking fevers, a salmon-coloured rash, and joint pain and swelling. It can begin in childhood, where it is called systemic-onset juvenile idiopathic arthritis, or in adulthood. Treatment uses steroids and medicines that block interleukin-1 or interleukin-6 to settle inflammation and protect the joints.
How many clinical trials are available for Still Disease?
RareWays currently indexes 55 clinical trials for Still Disease, of which 14 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Still Disease come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Still Disease.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.